<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2208245808
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Onivyde pegylated liposomal
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        IRINOTECAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        4.3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Dispersion for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        4171.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="LES LABORATOIRES SERVIER INDUSTRIE" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            LES LABORATOIRES SERVIER INDUSTRIE
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 4377]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Servier Saudi Arabia Trading LLC
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            LES LABORATORIES SERVIER 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01C-PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What ONIVYDE pegylated liposomal is and how it works</p><p>ONIVYDE pegylated liposomal is a cancer medicine that contains the active substance irinotecan. This active substance is held in tiny lipid (fatty) particles called liposomes.</p><p>Irinotecan belongs to a group of cancer medicines called &lsquo;topoisomerase inhibitors&rsquo;. It blocks an enzyme called topoisomerase I, which is involved in the division of cell DNA. This prevents the cancer cells from multiplying and growing, and they eventually die.</p><p>The liposomes are expected to accumulate within the tumour and release the medicine slowly over time, thereby allowing it to act for longer.</p><p>&nbsp;</p><p>What ONIVYDE pegylated liposomal is used for</p><p>ONIVYDE pegylated liposomal is used to treat adult patients with metastatic pancreatic cancer (cancer of the pancreas that has already spread elsewhere in the body) whose previously cancer treatment included a medicine called gemcitabine. ONIVYDE pegylated liposomal is used in combination with other cancer medicines, called 5-fluorouracil and leucovorin.</p><p>&nbsp;</p><p>If you have any questions about how ONIVYDE pegylated liposomal works or why this medicine has been prescribed for you, ask your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Follow carefully all instructions given to you by your doctor. They may differ from the general information contained in this leaflet.</p><p>&nbsp;</p><p>Do not use ONIVYDE pegylated liposomal</p><p><strong>&nbsp;</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a history of a severe allergy to irinotecan, or any of the other ingredients of this medicine (listed in section 6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are breast-feeding.</p><p>&nbsp;</p><p>Warnings and precautions</p><p><strong>&nbsp;</strong></p><p>Talk to your doctor or nurse before you are given ONIVYDE pegylated liposomal</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever had any liver problems or jaundice</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever had lung disease or have previously received medicines (colony stimulating factors) to increase your blood count or radiation therapy</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking other medicines (see section &ldquo;Other medicines and ONIVYDE pegylated liposomal&rdquo;)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are planning to have a vaccination as many vaccinations must not be given during chemotherapy</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are on a controlled sodium diet as this medicine contains sodium.</p><p>Talk to your doctor or nurse immediately during treatment with ONIVYDE pegylated liposomal</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you feel sudden shortness of breath, flushing, headache, skin rash or hives (itchy rash with swollen red bumps on the skin that appear suddenly), itching, swelling around the eyes, tightness in the chest or throat during or shortly after your infusion</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you experience fever, chills or other symptoms of infection</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you get diarrhoea with frequent liquid stools and cannot control this after 12 to 24 hours of treatment (see below)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you get breathlessness or cough.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you experience signs or symptoms of a blood clot, like sudden pain and swelling in a leg or an arm, sudden onset of coughing, chest pain or difficulty breathing.</p><p>&nbsp;</p><p><u>What to do in case of diarrhoea</u></p><p>&nbsp;</p><p>As soon as the first liquid stool occurs, start drinking large volumes of rehydration fluids (е.g. water, soda water, fizzy drinks, soup) to avoid losing too much liquid and salts from your body. Contact your doctor immediately to give you a suitable treatment. Your doctor may give you a medicine which contains loperamide to begin treatment at home but it must not be used for longer than 48 consecutive hours. If loose stools persist, contact your doctor.</p><p>&nbsp;</p><p><u>Blood tests and medical examinations</u></p><p>Before you start treatment with ONIVYDE pegylated liposomal, your doctor will perform blood tests (or other medical examinations) to determine the best starting dose for you. You will need to have further (blood or other) tests during treatment so that your doctor can monitor your blood cells and assess how you are responding to the treatment. Your doctor may need to adjust the dose or your treatment.</p><p>&nbsp;</p><p>Children and adolescents</p><p><strong>&nbsp;</strong></p><p>ONIVYDE pegylated liposomal is not recommended for use in adolescents and children below the age of 18 years.</p><p>Other medicines and ONIVYDE pegylated liposomal</p><p><strong>&nbsp;</strong></p><p>Tell your doctor if you are taking, have recently taken or might take any other medicines.</p><p>It is especially important that you tell your doctor if you have been given irinotecan in any form earlier.</p><p>&nbsp;</p><p>ONIVYDE pegylated liposomal must not be used instead of other medicines containing irinotecan because it behaves differently when it is contained in the liposomes than when it is given in its free form.</p><p>&nbsp;</p><p>Tell your doctor, pharmacist or nurse if you are already having, or have recently had chemotherapy and/or radiotherapy or treatment with the antifungal medicine flucytosine.</p><p>&nbsp;</p><p>&nbsp;</p><p>It is also especially important that you tell your doctor if you are also taking the following medicines, since they reduce the level of irinotecan in your body:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; phenytoin, phenobarbital or carbamazepine (medicines used to treat convulsions and falls)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifampicin and rifabutin (medicines used to treat tuberculosis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St. John&acute;s wort (a plant-based medicine used to treat depression and low mood)</p><p>&nbsp;</p><p>It is especially important that you tell your doctor if you are also taking the following medicines, since they increase the level of irinotecan in your body:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ketoconazole, itraconazole or voriconazole (medicines used to treat fungal infections)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; clarithromycin (an antibiotic medicine used to treat bacterial infections)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, atazanavir (medicines against HIV infection)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; regorafenib (a medicine against certain forms of cancer)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; telaprevir (a medicine used to treat a liver disease called hepatitis C)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nefazodone (a medicine used to treat depression, low mood)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gemfibrozil (medicine used to treat high fat levels in the blood)</p><p>&nbsp;</p><p>ONIVYDE pegylated liposomal with food and drink</p><p><strong>&nbsp;</strong></p><p>Avoid eating grapefruits and drinking grapefruit juice while you are receiving ONIVYDE pegylated liposomal as it may increase the level of irinotecan in your body.</p><p>&nbsp;</p><p>Pregnancy, breast-feeding and fertility</p><p><strong>&nbsp;</strong></p><p>You should not be given ONIVYDE pegylated liposomal if you are pregnant as it may harm the baby. Tell your doctor if you are or think you may be pregnant. Ask your doctor for advice if you are planning to have a baby. If you are given ONIVYDE pegylated liposomal you should not breast-feed until one month after the last dose.</p><p>&nbsp;</p><p>Prior to taking this medicine talk with your doctor about the possible risk with this medicine and the options that may preserve your ability to have children.</p><p>During your ONIVYDE pegylated liposomal treatment and for seven months after you should choose an effective birth control method which suits you to prevent pregnancy in this period of time. Males should use condoms during ONIVYDE pegylated liposomal treatment and for 4 months thereafter.</p><p>Tell your doctor if you are breast-feeding. You must not be given ONIVYDE pegylated liposomal if you are breast-feeding as this may be harmful to your baby.</p><p>&nbsp;</p><p>Driving and using machines</p><p>ONIVYDE pegylated liposomal may influence your ability to drive and use machines (as you may be sleepy, dizzy and exhausted with the use of ONIVYDE pegylated liposomal). You should avoid driving, using machines or performing other tasks that need full attention if you feel sleepy, dizzy and exhausted.</p><p>&nbsp;</p><p>ONIVYDE pegylated liposomal contains sodium</p><p>&nbsp;</p><p>This medicine contains 33,1 mg sodium (main component of cooking/table salt) in each vial. This is equivalent to 1,65% of the recommended maximum daily dietary intake of sodium for an adult.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>ONIVYDE pegylated liposomal must only be given by healthcare professionals trained in giving anticancer medicines.</p><p>Carefully follow all instructions given to you by your doctor or nurse.</p><p>&nbsp;</p><p>Your doctor will decide upon the doses you will receive.</p><p>ONIVYDE pegylated liposomal is given as a drip (infusion) into a vein, which should take at least 90 minutes and should be given as a single dose.</p><p>After you have been given ONIVYDE pegylated liposomal you will be given two other medicines, leucovorin and 5-fluorouracil.</p><p>The treatment will be repeated every two weeks.</p><p>In certain cases, lower doses or longer dosing intervals may be required.</p><p>&nbsp;</p><p>You may receive pre-medication against nausea and vomiting. If you have experienced sweating, abdominal cramping and salivation together with early frequent and liquid stools in previous treatments with ONIVYDE pegylated liposomal, you may receive additional medicines before ONIVYDE pegylated liposomal to prevent or reduce this in the following treament cycles.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. It is important that you are aware of what these side effects may be.</p><p>&nbsp;</p><p>Your doctor may also prescribe other medicines to help control your side effects.</p><p>Tell your doctor or nurse about any of the following serious side effects straight away:</p><p><strong>&nbsp;</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you experience swelling under the skin (angioedema) and/or symptoms of possible anaphylactic/anaphylactoid reactions such as sudden shortness of breath, flushing, nausea, headache, skin rash or hives (itchy rash with swollen red bumps on the skin that appear suddenly), itching, swelling around the eyes, and tightness in the chest or throat during the infusion or shortly after it. Severe allergic reactions may be life threatening.The infusion may need to be stopped and you may need to be treated or observed for the side effects</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you get fever, chills and signs of an infection (as this might require immediate treatment)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe persistent diarrhoea (liquid and frequent stools)&mdash;see section 2</p><p>&nbsp;</p><p>The following other side effects may occur:</p><p><strong>&nbsp;</strong></p><p><strong>Very common </strong>(may affect more than 1 in 10 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low levels of white blood cells (neutropenia and leukopenia), Low level of red blood cells (anaemia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low level of blood platelets (thrombocytopenia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea (loose or watery and frequent stools)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea and vomiting</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain in the stomach or in the gut area</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sore mouth</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of weight</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of appetite</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of body fluid (dehydration)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low level of salts (electrolytes) in the body (e.g. of potassium, magnesium)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unusual hair loss</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tiredness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling and fluid retention in the soft tissues (peripheral oedema)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Soreness and swelling of the digestive tract lining (mucosal inflammation)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Generalised weakness</p><p>&nbsp;</p><p><strong>Common </strong>(may affect up to 1 in 10 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chills</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections, for example fungal infections in the mouth (oral candidiasis), fever with low counts of white blood cells (febrile neutropenia), infections related to the administration of the product into a vein</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the stomach and the guts (gastroenteritis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Systemic body inflammation, caused by infection (sepsis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Potentially life-threatening complication of whole body inflammation (septic shock)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infection of the lungs (pneumonia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low level of white blood cells subtype, called lymphocytes with important function for the immune system (lymphopenia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decrease in some salts (electrolytes) in the body (e.g. phosphate, sodium)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood sugar (hypoglycaemia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sleeplessness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bad taste in the mouth</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A syndrome called cholinergic syndrome with sweating, salivation and abdominal cramping</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood pressure (hypotension)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Formation of a blood clot in a deep vein (deep vein thrombosis) or blockage of the main artery of the lung or one of its branches (pulmonary embolism), or blockage due to a blood clot elsewhere in the blood stream (embolism)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Voice impairment, hoarse or excessively breathy voice</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation in the gut</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Piles(haemorrhoids)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increases in liver enzymes (alanine aminotransferase or aspartate aminotransferase) in laboratory blood tests</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase in bilirubin levels (an orange-yellow pigment, waste product of the normal breakdown of the red blood cells) in other laboratory measurements related to liver function</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase in other laboratory measurements (increased international normalized ratio) related to the blood clotting system function</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormally low blood levels of albumin (major protein in the body)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Itching</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudden problems with kidney function which may lead to rapid deterioration or loss of the kidney function</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal reaction to the infusion causing symptoms like shortness of breath, flushing, headache, tightness in the chest or throat</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal fluid retention in the body causing swelling in the affected tissues (oedema)</p><p><strong>Uncommon </strong>(may affect up to 1 in 100 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Systemic body inflammation, caused by infection of the gall bladder and bile ducts (biliary sepsis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reaction to ONIVYDE pegylated liposomal (the active substance or the excipients)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diminished availability of oxygen to the body tissues</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the oesophagus (food pipe)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Formation or presence of a blood clot within a blood vessel &ndash; vein or artery (thrombosis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the lining of the rectum (the end of the large intestine)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hives (swollen red bumps)</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin rash</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Type of rash, characterised by appearance of a flat, red area on the skin covered with bumps (maculo-papular rash)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Change in the colour of the nail plates</p><p>&nbsp;</p><p>Not known (frequency cannot be estimated from the available data)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reddening of the skin</p><p>Reporting of side effects</p><p><strong>&nbsp;</strong></p><p>If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and vial after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Store in a refrigerator (2&deg;C - 8&deg;C). Do not freeze.</p><p>Keep the vial in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>Once the concentrate has been diluted for infusion with 5% glucose solution for injection or sodium chloride 9 mg/ml (0.9%) solution for injection, the dispersion should be used as soon as possible, but may be stored at ambient temperature (15&deg;C to 25&deg;C) for up to 6 hours. The diluted dispersion for infusion can be stored in the refrigerator (2&deg;C - 8&deg;C) for no more than 24 hours prior to use. It must be protected from light, and it must not be frozen.</p><p>Do not throw away this medicine via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What ONIVYDE pegylated liposomal contains</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is irinotecan. One 10 ml vial of concentrate contains 43 mg irinotecan anhydrous free base (as sucrosofate salt in a pegylated liposomal formulation).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are: 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC); cholesterol,</p><p>N-(carbonyl-methoxypolyethylene glycol-2000)-1,2-distearoly-sn-glycero-3-phosphoethanolam ine (MPEG-2000-DSPE); sucrose</p><p>octasulphate; 2- [4- (2-Hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES buffer); sodium chloride and water for injections. ONIVYDE pegylated liposomal contains sodium, if you are on a controlled sodium diet, see section 2.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                ONIVYDE pegylated liposomal is supplied as a white to slightly yellow opaque isotonic liposomal dispersion in a glass vial.

Each pack contains one vial with 10 ml of concentrate.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder</p><p>Les Laboratoires Servier 50, rue Carnot</p><p>92284 Suresnes cedex France</p><p>&nbsp;</p><p>Manufacturer</p><p>Les Laboratoires Servier Industrie 905 Route de Saran</p><p>45520 Gidy France</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                22 August 2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو أونيفايد ليبوسومال بالبولي إيثيلين غلايكول </strong><strong>ONIVYDE pegylated liposomal</strong><strong> وكيف يعمل؟</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">أونيفايد ليبوسومال بالبولي إيثيلين غلايكول ONIVYDE pegylated liposomal دواء مضاد للسرطان مادته الفعالة هي الارينوتيكان. هذه المادة الفعالة موجودة في جزيئات دهنية صغيرة تسمى الليبوزومات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينتمي إرينوتيكان إلى مجموعة من الأدوية المضادة للسرطان تسمى &laquo;مثبطات توبويزوميراز&raquo;. يكبح الأنزيم المسمى توبويزوميراز الذي يتدخل في تضاعف الحمض النووي للخلايا. وبالتالي يمنع الخلايا السرطانية من التكاثر والنمو لتموت في النهاية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تتراكم الجسيمات الشحمية (الليبوزومات) في الورم وتطلق الدواء ببطء مع مرور الوقت، مما يُمكّنه من العمل لفترة أطول.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ماهي الحالات التي يُستعمل فيها أونيفايد ليبوسومال بالبولي إيثيلين غلايكول </strong><strong>ONIVYDE pegylated liposomal</strong><strong>؟</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يوصف أونيفايد ليبوسومال بالبولي إيثيلين غلايكول ONIVYDE pegylated liposomal لعلاج سرطان البنكرياس النقيلي (سرطان البنكرياس الذي انتشر بالفعل في جزء آخر من الجسم) عند المرضى الذين سبق لهم تلقي علاج آخر مضاد للسرطان يشمل الجيمسيتابين. يستخدم أونيفايد ليبوسومال بالبولي إيثيلين غلايكول ONIVYDE pegylated liposomal مع أدوية أخرى مضادة للسرطان مثل 5-فلورويوراسيل وليكوفورين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة حول كيفية عمل أونيفايد ليبوسومال بالبولي إيثيلين غلايكول ONIVYDE pegylated liposomal أو لماذا تم وصف هذا الدواء لك، اسأل طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">اتبع بعناية جميع التعليمات التي يقدمها لك طبيبك. يمكن أن تكون مختلفة عن المعلومات العامة الواردة في هذه النشرة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>لا تستعمل أبداً أونيفايد ليبوسومال بالبولي إيثيلين غلايكول </strong><strong>ONIVYDE pegylated liposomal</strong><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك سوابق تخص حالات الحساسية الحادة تجاه ايرينوتيكان أو أي من المكونات الأخرى التي يحتوي عليها هذا الدواء (مشار إليها في االفقرة 6).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت ترضعين.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">استشر الطبيب أو الممرض(ة) قبل استعمال أونيفايد ليبوسومال بالبولي إيثيلين غلايكول ONIVYDE pegylated liposomal</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك سوابق تخص مشاكل في الكبد أو اليرقان.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك سوابق تخص أمراض الرئة أو العلاج الإشعاعي أو إذا تلقيت أدوية (عوامل نمو الخلايا) الرامية إلى زيادة عدد خلايا الدم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أدوية أخرى (أنظر قسم &laquo;أدوية أخرى وأونيفايد ليبوسومال بالبولي إيثيلين غلايكول ONIVYDE pegylated liposomal&raquo;).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تنوي الخضوع للتلقيح لأن العديد من اللقاحات تكون ممنوعة أثناء العلاج الكيميائي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتبع نظامًا غذائيًا منخفض الصوديوم مراقبا، لأن هذا الدواء يحتوي على الصوديوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">استشر الطبيب أو الممرض(ة) على الفور أثناء علاجك بأونيفايد ليبوسومال بالبولي إيثيلين غلايكولب ONIVYDE pegylated liposomal :</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا شعرت فجأة بضيق في التنفس،هبات ساخنة، أوجاع الرأس، طفح جلدي أو شري (حكة مع ظهور مفاجئ لنتوءات حمراء منتفخة على الجلد)، حكة، تورم حول العينين، ضيق في الصدر أو الحلق أثناء التروية أو بعدها بفترة قصيرة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تشعر بحمى أو قشعريرة أو غير ذلك من أعراض العدوى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبت بإسهال مصحوب ببراز سائب متكرر ومستمر بعد 12 إلى 24 ساعة من العلاج (انظر أدناه).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا شعرت بضيق في التنفس أو كنت تعاني من السعال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا شعرت بأي علامات أو أعراض قد تشير إلى تشكل خثرة دموية في الوريد أو الشريان مثل ألم مفاجئ مصاحب لتورم في الرجل أو الذراع، ظهور مفاجئ للسعال، ألم في الصدر أو صعوبة في التنفس.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>ما العمل في حالة الإسهال</u></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">عند ظهور البراز السائب الأول، يجب أن تشرب على الفور سوائل معالجة الجفاف بكميات وفيرة (على سبيل المثال، ماء، ماء فوار، مشروبات غازية، حساء) لتجنب فقدان جسمك للكثير من السوائل والأملاح. اتصل بطبيبك على الفور ليصف لك علاجا مناسبا. يمكن أن يصف لك طبيبك دواء يحتوي على اللوبراميد لبدء العلاج المنزلي، ولكن لا ينبغي تناول هذا الدواء لمدة تزيد عن 48 ساعة متتالية. إذا استمر البراز السائب، اتصل بطبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>تحاليل الدم والفحوصات الطبية</u></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">قبل أن تبدأ العلاج بأونيفايد ليبوسومال بالبولي إيثيلين غلايكولب ONIVYDE pegylated liposomal، يتعين على طبيبك إجراء تحاليل الدم (أو فحوصات طبية أخرى) لتحديد الجرعة الأولى الأنسب. يتعين عليك إجراء تحاليل أخرى (دم أو غيرها) أثناء العلاج ليتمكن طبيبك من مراقبة خلايا الدم وتقييم الاستجابة للعلاج. قد يحتاج طبيبك إلى تعديل الجرعة أو العلاج.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأطفال واليافعون</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">لا ينصح باستخدام أونيفايد ليبوسومال بالبولي إيثيلين غلايكولب ONIVYDE pegylated liposomal بالنسبة لليافعين والأطفال دون سن 18 عامًا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أدوية أخرى وأونيفايد ليبوسومال بالبولي إيثيلين غلايكولب </strong><strong>ONIVYDE pegylated liposomal</strong><strong> </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">من الأهمية بمكان أن تخبر طبيبك إذا تم وُصف لك ايرينوتيكان بأي شكل من الأشكال.</p><p dir="RTL">لا ينبغي استبدال أونيفايد ليبوسومال بالبولي إيثيلين غلايكولب ONIVYDE pegylated liposomal بأدوية أخرى تحتوي على ايرينوتيكان، لأنه يتصرف بشكل مختلف عند يكون في الجسيمات الشحمية (الليبوزومات) أو عندما يتم إعطاؤه في شكله الحر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر الطبيب أو الصيدلي أو الممرض(ة) إذا كنت قد تلقيت مؤخرًا علاجًا كيميائيًا و/ أو علاجًا إشعاعيًا أو علاجًا بدواء فلوسيتوزين المضاد للفطريات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من المهم جدًا أن تخبر أيضًا طبيبك إذا كنت كذلك تتناول الأدوية التالية، لأنها تخفض مستوى إرينوتيكان في جسمك:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينيتوين، فينوباربيتال أو كاربامازيبين (أدوية مستخدمة في علاج التشنجات والنوبات)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين وريفابوتين (أدوية مستخدمة في علاج السل).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة سانت جون (عشبة طبية تُستخدم في علاج حالات ونوبات الاكتئاب)</p><p dir="RTL">&nbsp;</p><p dir="RTL">من الأهمية بمكان أن تخبر طبيبك إذا كنت تتناول أيضًا الأدوية التالية، لأنها تزيد من مستوى إرينوتيكان في جسمك:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كيتوكونازول، إيتراكونازول أو فوريكونازول (أدوية مستخدمة في علاج الالتهابات الفطرية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كلاريثروميسين (مضاد حيوي يستخدم في علاج الالتهابات البكتيرية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إندينافير، لوبينافير، نلفينافير، ريتونافير، ساكوينافير، أتازانافير (أدوية مستخدمة في علاج عدوى فيروس نقص المناعة البشرية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريجورافينيب (دواء يستخدم في علاج بعض أنواع السرطان).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تيلابريفير (دواء يستخدم في علاج التهاب الكبد الويائي سي، وهو مرض كبدي).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نيفازودون (دواء يستخدم في علاج حالات ونوبات الاكتئاب).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جمفبروزيل (دواء يستخدم في علاج فرط كوليسترول الدم).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أونيفايد ليبوسومال بالبولي إيثيلين غلايكولب </strong><strong>ONIVYDE pegylated liposomal</strong><strong> مع الأطعمة والمشروبات</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">تجنب تناول الليمون الهندي وشرب عصير الليمون الهندي أثناء تناولك أونيفايد ليبوسومال بالبولي إيثيلين غلايكولب ONIVYDE pegylated liposomal لأن هذه الفاكهة ترفع مستوى إرينوتيكان في جسمك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة والخصوبة</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يتعين عليك ألا تتناولي أونيفايد ليبوسومال بالبولي إيثيلين غلايكولب ONIVYDE pegylated liposomal إذا كنت حاملاً لأنه قد يضر بالجنين. أخبري طبيبك إذا كنت أو تعتقدين أنك حامل. إذا كنت تخططين للحمل، استشيري طبيبك إذا كنت تعالجين بأونيفايد ليبوسومال بالبولي إيثيلين غلايكولب ONIVYDE pegylated liposomal، فلا يجب عليك الإرضاع خلال الشهر الذي يلي آخر استعمال</p><p dir="RTL">&nbsp;</p><p dir="RTL">قبل تناول هذا الدواء، ناقش مع طبيبك المخاطر المحتملة المرتبطة بهذا الدواء والخيارات المتاحة للحفاظ على قدرتك على إنجاب الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتعين عليك استخدام وسيلة فعالة لمنع الحمل مناسبة لك أثناء العلاج بأونيفايد ليبوسومال بالبولي إيثيلين غلايكولب ONIVYDE pegylated pegylated liposomal ولمدة سبعة أشهر بعد التوقف عن العلاج لتجنب الحمل خلال هذه الفترة. يتعين على الرجال استخدام الواقي الذكري أثناء العلاج بأونيفايد ليبوسومال بالبولي إيثيلين غلايكولب ONIVYDE pegylated pegylated liposomal ولمدة تصل إلى 4 أشهر بعد التوقف عن العلاج</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت ترضعين، أخبري طبيبك. يجب ألا تتعالجي بأونيفايد ليبوسومال بالبولي إيثيلين غلايكولب ONIVYDE pegylated pegylated liposomal إذا كنت ترضعين لأنه قد يضر بالجنين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>سياقة المركبات واستخدام الآلات</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يمكن أن يؤثر أونيفايد ليبوسومال بالبولي إيثيلين غلايكولب ONIVYDE pegylated pegylated liposomal على قدرتك على السياقة واستخدام الآلات (لأنه قد يسبب النعاس والدوار والتعب الشديد). تجنب السياقة أو استخدام الآلات أو أداء أي مهام أخرى تتطلب تركيز انتباهك الكامل إذا شعرت بالنعاس أو الدوار أو التعب الشديد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي أونيفايد ليبوسومال بالبولي إيثيلين غلايكولب</strong><strong>ONIVYDE pegylated liposomal</strong><strong> على الصوديوم.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يحتوي هذا الدواء على 33.1 ملغ من الصوديوم (المكون الرئيسي لملح المطبخ / المائدة) في كل قنينة. وهذا يعادل 1.65٪ من الحد الأقصى الموصى به يوميًا من الصوديوم للبالغين.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا ينبغي أن يُستعمل أونيفايد ليبوسومال بالبولي إيثيلين غلايكول ONIVYDE pegylated liposomal إلا من قبل متخصصين في الرعاية الصحية من ذوي الخبرة في استخدام الأدوية المضادة للسرطان.</p><p dir="RTL">اتبع بعناية جميع التعليمات التي يُقدمها لك الطبيب أو الممرض(ة).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يقرر طبيبك الجرعات التي تُعطى لك.</p><p dir="RTL">يُعطى أونيفايد ليبوسومال بالبولي إيثيلين غلايكول ONIVYDE pegylated liposomal في وريد بالتقطير (تروية) لمدة 90 دقيقة على الأقل في جرعة واحدة.</p><p dir="RTL">بعد أونيفايد ليبوسومال بالبولي إيثيلين غلايكول ONIVYDE pegylated liposomal، ستتلقى دوائين آخرين: ليوكوفورين و 5-فلورويوراسيل.</p><p dir="RTL">يُعطى العلاج كل أسبوعين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في بعض الحالات، قد يكون من الضروري تقليص الجرعات أو زيادة الفترة بين إعطاءات العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قبل العلاج بأونيفايد ليبوسومال بالبولي إيثيلين غلايكول ONIVYDE pegylated liposomal، قد تُعطى علاجًا ضد الغثيان والقيء. إذا كنت قد عانيت من أي وقت مضى من براز مبكر ومتكرر وسائب مصحوب بتعرق وتشنجات في البطن ولعاب مفرطفرط أثناء علاج بأونيفايد ليبوسومال بالبولي إيثيلين غلايكول ONIVYDE pegylated liposomal، فسوف يتم إعطاؤك أدوية أخرى لتجنب أو الحد من هذه الآثار خلال دورات العلاج الموالية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى حول استعمال هذا الدواء، اسأل الطبيب أو الممرض(ة).</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كباقي الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، على الرغم من عدم حدوثها عند الجميع. من المهم أن تعرف الآثار الجانبية المحتملة لهذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أيضًا لطبيبك أن يصف لك أدوية أخرى للمساعدة في التحكم فيها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر الطبيب أو الممرض(ة) على الفور إذا لاحظت أيًا من الآثار الجانبية الخطيرة التالية:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تشعر بتورم تحت الجلد (وذمة وعائية) و/ أو أعراض ردود فعل تحسسية / تأقية محتملة مثل ضيق مفاجئ في التنفس، هبات ساخنة، غثيان، صداع ، طفح جلدي أو شرى ( حكة مفاجئة مصحوبة بظهور نتوءات حمراء منتفخة على الجلد ، حكة.، تورم حول العينين، ضيق في الصدر أو الحلق أثناء أو بعد فترة وجيزة من الحقن. يمكن لردود الفعل التحسسية الشديدة أن تعرض حياتك للخطر. قد تضطر إلى توقيف التروية أو قد تحتاج إلى العلاج أو البقاء تحت الملاحظة لأي بسبب أحد هذه الآثار الجانبية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حمى أو قشعريرة أو غيرها من أعراض العدوى (لأن هذا قد يتطلب علاجًا فوريًا).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك إسهال حاد مستمر (براز سائب متكرر)، انظر الفقرة 2.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد تظهر الآثار الجانبية الأخرى التالية:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>شائعة جدًا </strong>(قد تصيب أكثر من 1 من كل 10 مرضى)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى خلايا الدم البيضاء (قلة العدلات ونقص الكريات البيض) وخلايا الدم الحمراء (فقر الدم) والصفائح الدموية (قلة الصفيحات الدموية) في الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال (براز سائب أو سائل ومتكرر)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان وقيء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام في المعدة أو آلام في الأمعاء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الفم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن وفقدان الشهية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إجتفاف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مستويات منخفضة من الأملاح (الشوارد) في الدم (مثل البوتاسيوم والمغنيسيوم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط غير عادي للشعر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعب، عياء معمم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إحساس بالدوار</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم واحتباس الماء في الأنسجة الرخوة (وذمة محيطية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأغشية المخاطية الهضمية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حُمى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف عام</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة (قد تهم ما يصل إلى 1 من كل 10 مرضى)</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قشعريرة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهابات، مثل الالتهابات الفطرية في الفم (القلاع الفموي)، الحمى مع انخفاض عدد خلايا الدم البيضاء (قلة العدلات الحموية)، الالتهابات المرتبطة بإعطاء المنتج عن طريق التسريب في الوريد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المعدة والأمعاء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى معممة في الجسم (تعفن الدم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المضاعفات المرتبطة بعدوى التي يمكن أن تعرض الحياة للخطر (صدمة إنتانية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الرئة (الالتهاب الرئوي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الخلايا الليمفاوية في الدم (قلة الخلايا اللمفية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في بعض الأملاح (الشوارد) في الجسم (مثل الفوسفات والصوديوم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض نسبة السكر في الدم (نقص السكر في الدم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أرق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طعم سيئ في الفم.(خلل التذوق)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة تسمى متلازمة كوليني مصحوبة بتعرق ولعاب مفرط وتشنجات البطن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تكوين خثرة في الشبكة الوريدية العميقة (الخثار الوريدي العميق)، أو انسداد الشريان الرئوي (صمة رئوية) أو في شريان آخر (انسداد) بسبب خثرة منتشرة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب في الصوت (خلل النطق)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأمعاء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البواسير</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل في اختبارات دم الكبد (زيادة ألانين أمينوترانسفيراز، أسبارتات أمينوترانسفيراز)، زيادة البيليروبين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة INR (النسبة المعيارية الدولية) المرتبطة بوظيفة تخثر الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الألبومين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إصابة مفاجئة في وظائف الكلى التي قد يؤدي إلى تدهور سريع أو فقدان وظائف الكلى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل غير طبيعي على التسريب يسبب أعراضًا مثل ضيق في التنفس، هبات ساخنة، صداع، ضيق في الصدر أو الحلق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتباس غير طبيعي للماء في الجسم يؤدي إلى تورم الأنسجة المتأثرة (وذمة)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة (قد تهم ما يصل 1 من كل 100 مريض)</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى جهازية معممة بنقطة انطلاق صفراوية (تعفن صفراوي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل تحسسي تجاه أونيفايد ليبوسومال بالبولي إيثيلين غلايكول ONIVYDE pegylated liposomal (المادة الفعالة أو السواغات)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص الأكسجين في الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المريء (الأنبوب الذي يمر منه الطعام)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تكوين أو وجود خثرة دموية في وعاء دموي (تخثر الدم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الغشاء المخاطي للمستقيم (آخر الأمعاء الغليظة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشرى (بقع حمراء منتفخة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي يتميز بظهور احمرار على الجلد مغطى ببثور (طفح بقعي حطاطي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في لون الأظافر</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تردد غير محدد </strong>(لا تمكن البيانات المتاحة من تقدير نسبة التردد).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الجلد</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">إذا شعرتم بأي أثر جانبي، يُرجي التحدث بشأنه مع الطبيب أو الممرض(ة). ينطبق هذا أيضا على أي أثر جانبي لم تتم الإشارة إليه في هذه النشرة. إذا شعرت بأي تأثير جانبي، يُرجي التحدث بشأنه مع الطبيب أو الممرض(ة). ينطبق هذا أيضا على أي أثر جانبي لم تتم الإشارة إليه في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ بعيدًا عن أنظار ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على التغليف والقنينة&nbsp; يحيل تاريخ انتهاء الصلاحية إلى اليوم الأخير من نفس الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُحفظ في الثلاجة (بين 2 و 8 درجات مئوية).</p><p dir="RTL">لا يُجمد</p><p dir="RTL">تُحفظ القنينة في التغليف الخارجي بعيداً عن الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعد التخفيف في محلول جلوكوز بنسبة 5٪ للحقن أو في محلول كلوريد الصوديوم نسبة 9 ملغ / مل (0.9٪)، يتعين استخدام المحلول في أسرع وقت ممكن، ولكن يمكن تخزينه لمدة 6 ساعات في درجة الحرارة المحيطة ( بين15 و 25 درجة مئوية). يمكن تخزين المحلول المخفف للتروية لمدة تصل إلى 24 ساعة في الثلاجة ( بين 2 و 8 درجات مئوية) قبل الاستخدام. يجب تحفظه بعيدًا عن الضوء ولا يجب تجميده.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من هذا الدواء في بالوعة مياه الصرف الصحي أو مع النفايات المنزلية. اطلب من الصيدلي التخلص من الأدوية التي لم تعد تستخدمها. تساهم هذه التدابير في حماية البيئة</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما ذا يحتوي أونيفايد ليبوسومال بالبولي إيثيلين غلايكول </strong><strong>ONIVYDE pegylated liposomal</strong><strong> </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي ايرينوتيكان. قنينة واحدة من سعة 10 مل من محلول يُخفّف تحتوي على 43 ملغ من مادة إيرينوتيكان اللامائية الحرة (في شكل سوكروسوفيت في تركيبة شحمية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشمل المكونات الأخرى: 1،2- ديستيريول-سن-جليسيرو- 3- فوسفوكولين (DSPC)؛ كوليسترول؛ن-(كاربونيل ميثوكسي بولي إيثيلين جلايكول -2000) -1،2 ديستيريول-سن-جليسيرو- 3-فوسفويثانولامين (MPEG-2000-DSPE)؛ السكروز أوكتاسلفات؛ عازل حمضي2- [4- (2-هيدروكسي إيثيل) -1-بيبرازين] إيثان سلفونيك (عازل HEPES)؛ كلوريد الصوديوم وماء مستحضرات قابلة للحقن. يحتوي أونيفايد ليبوسومال بالبولي إيثيلين غلايكولبONIVYDE pegylated liposomal على الصوديوم. انظر الفقرة 2 إذا كنت تتبع نظامًا غذائيًا منخفض الصوديوم مراقبًا.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هو أونيفايد ليبوسومال بالبولي إيثيلين غلايكولب </strong><strong>ONIVYDE pegylated liposomal</strong><strong> وما هي محتويات التغليف الخارجي</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">أونيفايد ليبوسومال بالبولي إيثيلين غلايكولب ONIVYDE pegylated liposomal محلول شحمي متساوي التوتر لونه أبيض مائل إلى الصفرة قليلاً، معبأ في قنينة</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي كل علبة على قنينة واحدة من سعة 10 مل من المحلول الذي يُخفف</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>اسم وعنوان حامل ترخيص طرح الدواء في الأسواق.</strong></p><p dir="RTL">Les Laboratoires Servier</p><p dir="RTL">50, rue Carnot</p><p dir="RTL">92284 Suresnes Cedex</p><p dir="RTL">فرنسا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المُصنع</strong></p><p dir="RTL">Les Laboratoires Servier Industrie</p><p dir="RTL">905 Route de Saran</p><p dir="RTL">45520 Gidy</p><p dir="RTL">فرنسا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            22\08\2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ONIVYDE pegylated liposomal 4.3 mg/ml concentrate for dispersion for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One 10 ml vial of concentrate contains 43 mg irinotecan anhydrous free base (as irinotecan sucrosofate salt in a pegylated liposomal formulation).
One ml of concentrate contains 4.3 mg irinotecan anhydrous free base (as irinotecan sucrosofate salt in a pegylated liposomal formulation).
Excipient with known effect
One ml of concentrate contains 0.144 mmol (3.31 mg) sodium.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for dispersion for infusion.
White to slightly yellow opaque isotonic liposomal dispersion.
The concentrate has a pH of 7.2 and an osmolality of 295 mOsm/kg.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of metastatic adenocarcinoma of the pancreas, in combination with 5-fluorouracil (5-FU) and leucovorin (LV), in adult patients who have progressed following gemcitabine based therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ONIVYDE pegylated liposomal must only be prescribed and administered to patients by healthcare professionals experienced in the use of anti-cancer therapies.</p><p>ONIVYDE pegylated liposomal is not equivalent to non-liposomal irinotecan formulations and should not be interchanged.</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p>ONIVYDE pegylated liposomal, leucovorin and 5-fluorouracil should be administered sequentially. The recommended dose and regimen of ONIVYDE pegylated liposomal is 70 mg/m<sup>2</sup> intravenously over 90 minutes, followed by LV 400 mg/m<sup>2</sup> intravenously over 30 minutes, followed</p><p>by 5-FU 2,400 mg/m<sup>2</sup> intravenously over 46 hours, administered every 2 weeks. ONIVYDE pegylated liposomal should not be administered as a single agent.</p><p>A reduced starting dose of ONIVYDE pegylated liposomal of 50 mg/m<sup>2</sup> should be considered for patients known to be homozygous for the UGT1A1*28 allele (see sections 4.8 and 5.1). A dose increase of ONIVYDE pegylated liposomal to 70 mg/m<sup>2</sup> should be considered if tolerated in subsequent cycles.</p><p>&nbsp;</p><p><em><u>Pre-medication</u></em></p><p>It is recommended that patients receive pre-medication with standard doses of dexamethasone (or an equivalent corticosteroid) together with a 5-HT3 antagonist (or other antiemetic) at least 30 minutes prior to ONIVYDE pegylated liposomal infusion.</p><p><em><u>Dose adjustments</u></em></p><p>All dose modifications should be based on the worst preceding toxicity. The LV dose does not require adjustment. For Grade 1 and 2 toxicities there are no dose modifications recommended. Dose adjustments, as summarised in Table 1 and Table 2, are recommended to manage</p><p>Grade 3 or 4 toxicities related to ONIVYDE pegylated liposomal.</p><p>&nbsp;</p><p>For patients who start treatment with 50 mg/m<sup>2</sup> ONIVYDE pegylated liposomal and do not dose escalate to 70 mg/m<sup>2</sup>, the recommended first dose reduction is to 43 mg/m<sup>2</sup> and the second dose reduction is to 35 mg/m<sup>2</sup>. Patients who require further dose reduction should discontinue treatment.</p><p>&nbsp;</p><p>Patients who are known to be homozygous for UGT1A1*28 and without drug related toxicities during the first cycle of therapy (reduced dose of 50 mg/m<sup>2</sup>) may have the dose of ONIVYDE pegylated liposomal increased to a total dose of 70 mg/m<sup>2</sup> in subsequent cycles based on individual patient tolerance.</p><p>Table 1: Recommended dose modifications for ONIVYDE pegylated liposomal +5-FU/LV for Grade 3-4 toxicities for patients not homozygous for UGT1A1*28</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><em>Toxicity grade (value) by NCI CTCAE v 4.0<sup>1</sup></em></strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>ONIVYDE pegylated liposomal /5-FU adjustment (for patients not homozygous for UGT1A1*28)</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Haematological toxicities</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong><u>Neutropenia</u></strong></p></td><td colspan="2" style="vertical-align:top"><p>A new cycle of therapy should not begin until the absolute neutrophil count is &ge; 1,500 cells/mm<sup>3</sup></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong><em>Grade 3 or</em></strong></p><p><strong><em>Grade 4 (&lt; 1,000 cells/mm<sup>3</sup>) </em>or <u>Neutropenic fever</u></strong></p></td><td style="vertical-align:top"><p><strong><em>First occurrence</em></strong></p></td><td style="vertical-align:top"><p>Reduce ONIVYDE pegylated liposomal dose to 50 mg/m<sup>2</sup></p><p>Reduce 5-FU dose by 25% (1,800 mg/m<sup>2</sup>).</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong><em>Second occurrence</em></strong></p></td><td style="vertical-align:top"><p>Reduce ONIVYDE pegylated liposomal dose to 43 mg/m<sup>2</sup></p><p>Reduce 5-FU dose by an additional 25% (1,350 mg/m<sup>2</sup>).</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Third occurrence</em></strong></p></td><td style="vertical-align:top"><p>Discontinue treatment</p></td></tr><tr><td style="vertical-align:top"><p><strong><u>Thrombocytopenia</u> <u>Leukopenia</u></strong></p></td><td colspan="2" style="vertical-align:top"><p>A new cycle of therapy should not begin until the platelet count is</p><p>&ge; 100,000 platelets/mm<sup>3</sup></p><p>Dose modifications for leukopenia and thrombocytopenia are based on NCI CTCAE toxicity grading and are the same as recommended for neutropenia above.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Non-haematological toxicities<sup>2</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong><u>Diarrhoea</u></strong></p></td><td colspan="2" style="vertical-align:top"><p>A new cycle of therapy should not begin until diarrhoea resolves to &le; Grade 1 (2-3 stools/day more than pre-treatment frequency).</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Grade 2</em></strong></p></td><td colspan="2" style="vertical-align:top"><p>A new cycle of therapy should not begin until diarrhoea resolves to &le; Grade 1 (2-3 stools/day more than pre-treatment frequency).</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><em>Toxicity grade (value) by NCI CTCAE v 4.0<sup>1</sup></em></strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>ONIVYDE pegylated liposomal /5-FU adjustment (for patients not homozygous for UGT1A1*28)</strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong><em>Grade 3 or 4</em></strong></p></td><td style="vertical-align:top"><p><strong><em>First occurrence</em></strong></p></td><td style="vertical-align:top"><p>Reduce ONIVYDE pegylated liposomal dose to 50 mg/m<sup>2</sup></p><p>Reduce 5-FU dose by 25% (1,800 mg/m<sup>2</sup>)</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong><em>Second occurrence</em></strong></p></td><td style="vertical-align:top"><p>Reduce ONIVYDE pegylated liposomal dose to 43 mg/m<sup>2</sup></p><p>Reduce 5-FU dose by an additional 25% (1,350 mg/m<sup>2</sup>)</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Third occurrence</em></strong></p></td><td style="vertical-align:top"><p>Discontinue treatment</p></td></tr><tr><td style="vertical-align:top"><p><strong><u>Nausea/vomiting</u></strong></p></td><td colspan="2" style="vertical-align:top"><p>A new cycle of therapy should not begin until nausea/vomiting resolves to &le; Grade 1 or baseline</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong><em>Grade 3 or 4 </em></strong><em>(despite antiemetic therapy)</em></p></td><td style="vertical-align:top"><p><strong><em>First occurrence</em></strong></p></td><td style="vertical-align:top"><p>Optimise antiemetic therapy</p><p>Reduce ONIVYDE pegylated liposomal dose to 50 mg/m<sup>2</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Second occurrence</em></strong></p></td><td style="vertical-align:top"><p>Optimise antiemetic therapy</p><p>Reduce ONIVYDE pegylated liposomal dose to 43 mg/m<sup>2</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Third occurrence</em></strong></p></td><td style="vertical-align:top"><p>Discontinue treatment</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><!--[if gte vml 1]><v:group
   id="Group_x0020_2" o:spid="_x0000_s1026" style='position:absolute;left:0;
   text-align:left;margin-left:5.4pt;margin-top:36.8pt;width:71.9pt;height:1.1pt;
   z-index:-16377344;mso-wrap-distance-left:0;mso-wrap-distance-right:0;
   mso-position-horizontal-relative:text;mso-position-vertical-relative:text'
   coordsize="9131,139" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Graphic_x0020_3" o:spid="_x0000_s1027" style='position:absolute;
    width:9131;height:139;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="913130,13970" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m912876,l,,,13715r912876,l912876,xe" fillcolor="black" stroked="f">
    <v:path arrowok="t"/>
   </v:shape></v:group><![endif]--><img width="95" height="1" src="file:///C:/Users/HNHZ_SA1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><strong><u>Hepatic, renal,</u> <u>respiratory or</u> other<sup>2</sup> toxicities <em>Grade 3 or 4</em></strong></p></td><td colspan="2" style="vertical-align:top"><p>A new cycle of therapy should not begin until the adverse reaction resolves to &le; Grade 1</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>First occurrence</em></strong></p></td><td style="vertical-align:top"><p>Reduce ONIVYDE pegylated liposomal dose to 50 mg/m<sup>2</sup></p><p>Reduce 5-FU dose by 25% (1,800 mg/m<sup>2</sup>)</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong><em>Second occurrence</em></strong></p></td><td style="vertical-align:top"><p>Reduce ONIVYDE pegylated liposomal dose to 43 mg/m<sup>2</sup></p><p>Reduce 5-FU dose by an additional 25% (1,350 mg/m<sup>2</sup>)</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Third occurrence</em></strong></p></td><td style="vertical-align:top"><p>Discontinue treatment</p></td></tr><tr><td style="vertical-align:top"><p><strong>Anaphylactic reaction</strong></p></td><td style="vertical-align:top"><p><strong><em>First occurrence</em></strong></p></td><td style="vertical-align:top"><p>Discontinue treatment</p></td></tr></tbody></table><p><sup>1</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NCI CTCAE v 4.0 = National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0</p><p><sup>2</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Excludes asthenia and anorexia; Asthenia and Grade 3 anorexia do not require dose adjustment.</p><p>&nbsp;</p><p>Table 2: Recommended dose modifications for ONIVYDE pegylated liposomal +5-FU/LV for Grade 3-4 toxicities in patients homozygous for UGT1A1*28</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><em>Toxicity grade (value) by NCI CTCAE v 4.0<sup>1</sup></em></strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>ONIVYDE pegylated liposomal /5-FU adjustment</strong></p><p><strong>(for patients homozygous for UGT1A1*28 without previous increase<sup>3</sup> to 70 mg/m<sup>2</sup>)</strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Adverse reactions<sup>2</sup></strong></p><p><strong><em>Grade 3 or 4</em></strong></p></td><td colspan="2" style="vertical-align:top"><p>A new cycle of therapy should not begin until adverse event resolves to &le; Grade 1</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong><em>First occurrence</em></strong></p></td><td style="vertical-align:top"><p>Reduce ONIVYDE pegylated liposomal dose to 43 mg/m<sup>2</sup></p><p>5-FU dose modification as in Table 1</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong><em>Second occurrence</em></strong></p></td><td style="vertical-align:top"><p>Reduce ONIVYDE pegylated liposomal dose to 35 mg/m<sup>2</sup></p><p>5-FU dose modification as in Table 1</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong><em>Third occurrence</em></strong></p></td><td style="vertical-align:top"><p>Discontinue treatment</p></td></tr></tbody></table><p>1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NCI CTCAE v 4.0 = National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0</p><p>2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Excludes asthenia and anorexia; asthenia and Grade 3 anorexia do not require dose adjustment.</p><p>3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In case of a dose increase of ONIVYDE pegylated liposomal to 70 mg/m<sup>2</sup> if tolerated in subsequent cycles, recommended dose modifications should follow Table 1.</p><p>&nbsp;</p><p><em><u>Special populations</u></em></p><p><em>Hepatic impairment</em></p><p>No dedicated hepatic impairment study has been conducted with ONIVYDE pegylated liposomal. The use of ONIVYDE pegylated liposomal should be avoided in patients with bilirubin &gt; 2.0 mg/dl, or aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &gt; 2.5 times upper limit of normal (ULN) or &gt; 5 times ULN if liver metastasis is present (see section 4.4).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No dedicated renal impairment study has been conducted with ONIVYDE pegylated liposomal. No dose adjustment is recommended in patients with mild to moderate renal impairment (see</p><p>sections 4.4 and 5.2). ONIVYDE pegylated liposomal is not recommended for use in patients with severe renal impairment (CLcr &lt; 30 ml/min).</p><p><em>Elderly</em></p><p>Forty-one percent (41%) of patients treated with ONIVYDE pegylated liposomal across the clinical program were &ge; 65 years. No dose adjustment is recommended.</p><p><em>Paediatric population</em></p><p>The safety and efficacy of ONIVYDE pegylated liposomal in children and adolescents aged &le; 18 years have not yet been established. No data are available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>ONIVYDE pegylated liposomal is for intravenous use. The concentrate must be diluted prior to administration and given as a single intravenous infusion over 90 minutes. For more details, see section 6.6.</p><p>&nbsp;</p><p><em>Precautions to be taken before handling or administering the medicinal product</em></p><p>ONIVYDE pegylated liposomal is a cytotoxic medicinal product. The use of gloves, goggles and protective clothing when handling or administering ONIVYDE pegylated liposomal is recommended. Pregnant staff should not handle ONIVYDE pegylated liposomal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                History of severe hypersensitivity to irinotecan or to any of the excipients listed in section 6.1. Breast-feeding (see section 4.6).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General</u></p><p>&nbsp;</p><p>ONIVYDE pegylated liposomal is a liposomal formulation of irinotecan with different pharmacokinetic properties compared to non-liposomal irinotecan. The dose concentration and strength are different in comparison to non-liposomal irinotecans.</p><p>&nbsp;</p><p>ONIVYDE pegylated liposomal is not equivalent to other non-liposomal irinotecan formulations and should not be interchanged.</p><p>&nbsp;</p><p>In the limited number of patients with prior exposure to non-liposomal irinotecan, no benefit of ONIVYDE pegylated liposomal has been demonstrated.</p><p><u>Myelosuppression/neutropenia</u></p><p>&nbsp;</p><p>Complete blood cell count monitoring is recommended during ONIVYDE pegylated liposomal treatment. Patients should be aware of the risk of neutropenia and the significance of fever. The median time to nadir for &ge; Grade 3 neutropenia is 23 (range 8-104) days post first dose of treatment with ONIVYDE pegylated liposomal. Febrile neutropenia (body temperature &gt; 38&deg;C and neutrophil count &le; 1,000 cells/mm&sup3;) should be urgently treated in the hospital with broad-spectrum intravenous antibiotics. ONIVYDE pegylated liposomal should be withheld if neutropenic fever occurs or the absolute neutrophil count drops below 1,500 cells/mm<sup>3</sup>. Sepsis with neutropenic fever and consequent septic shock with fatal outcome has been observed in patients with metastatic pancreatic adenocarcinoma treated with ONIVYDE pegylated liposomal.</p><p>In patients who experienced severe haematological events, a dose reduction or treatment discontinuation is recommended (see section 4.2). Patients with severe bone marrow failure should not be treated with ONIVYDE pegylated liposomal.</p><p>History of prior abdominal radiation increases the risk of severe neutropenia and febrile neutropenia following ONIVYDE pegylated liposomal treatment. Close monitoring of blood counts is recommended, and the use of myeloid growth factors should be considered for patients with a history of abdominal radiation. Caution should be exercised in patients receiving concurrent administration of ONIVYDE pegylated liposomal with irradiation.</p><p>Patients with deficient glucuronidation of bilirubin, such as those with Gilbert&rsquo;s syndrome, may be at greater risk of myelosuppression when receiving therapy with ONIVYDE pegylated liposomal.</p><p>&nbsp;</p><p>Compared to Caucasian patients, Asian patients have an increased risk of severe and febrile neutropenia following treatment with ONIVYDE pegylated liposomal +5-FU/LV (see sections 4.8 and 5.2).</p><p><u>Immunosuppressive effects and vaccines</u></p><p>&nbsp;</p><p>Administration of live or live-attenuated vaccines in patients immunocompromised by chemotherapeutic medicinal products including ONIVYDE pegylated liposomal may result in serious or fatal infections; therefore vaccination with a live vaccine should be avoided. Killed or inactivated vaccines may be administered; however, the response to such vaccines may be diminished.</p><p>&nbsp;</p><p><u>Interactions with strong CYP3A4 inducers</u></p><p>&nbsp;</p><p>ONIVYDE pegylated liposomal should not be administered with strong CYP3A4-enzyme inducers such as anticonvulsants (phenytoin, phenobarbital or carbamazepine), rifampin, rifabutin and St.</p><p>John&rsquo;s wort unless there are no therapeutic alternatives. The appropriate starting dose for patients taking these anticonvulsants or other strong inducers has not been defined. Consideration should be given to substituting with non-enzyme inducing therapies at least 2 weeks prior to initiation of ONIVYDE pegylated liposomal therapy (see section 4.5).</p><p>&nbsp;</p><p><u>Interactions with strong CYP3A4 inhibitors or strong UGT1A1 inhibitors</u></p><p>ONIVYDE pegylated liposomal should not be administered with strong CYP3A4-enzyme inhibitors (e.g. grapefruit juice, clarithromycin, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telaprevir, voriconazole). Strong CYP3A4 inhibitors should be discontinued at least 1 week prior to starting ONIVYDE pegylated liposomal therapy.</p><p>ONIVYDE pegylated liposomal should not be administered with strong UGT1A inhibitors (e.g. atazanavir, gemfibrozil, indinavir) unless there are no therapeutic alternatives.</p><p>&nbsp;</p><p><u>Diarrhoea</u></p><p>&nbsp;</p><p>Diarrhoea can occur early (onset in &le; 24 hours after starting ONIVYDE pegylated liposomal) or late (&gt; 24 hours) (see section 4.8).</p><p>In patients experiencing early diarrhoea, therapeutic and prophylactic atropine should be considered unless contraindicated. Patients should be made aware of the risk of delayed diarrhoea which can be debilitating and, on rare occasions, life threatening since persistent loose or watery stools can result in dehydration, electrolyte imbalance, colitis, gastrointestinal (GI) ulceration, infection or sepsis.</p><p>As soon as the first liquid stool occurs, the patient should start drinking large volumes of beverages containing electrolytes. Patients should have loperamide (or equivalent) readily available to begin treatment for late diarrhoea. Loperamide should be initiated at first occurrence of poorly formed or loose stools or at the earliest onset of bowel movements more frequent than normal. Loperamide should be given until patient is without diarrhoea for at least 12 hours.</p><p>If diarrhoea persists while patient is on loperamide for more than 24 hours, adding oral antibiotic support (e.g. fluoroquinolone for 7 days) should be considered. Loperamide should not be used for more than 48 consecutive hours due to risk of paralytic ileus. If diarrhoea persists for more</p><p>than 48 hours, stop loperamide, monitor and replace fluid electrolytes and continue antibiotic support until resolution for accompanying symptoms.</p><p>ONIVYDE pegylated liposomal treatment should be delayed until diarrhoea resolves</p><p>to &le; Grade 1 (2-3 stools/day more than pre-treatment frequency). ONIVYDE pegylated liposomal must not be administered to patients with bowel obstruction, and chronic inflammatory bowel disease, until it is resolved.</p><p>Following Grade 3 or 4 diarrhoea, the subsequent dose of ONIVYDE pegylated liposomal should be reduced, (see section 4.2).</p><p>&nbsp;</p><p><u>Cholinergic reactions</u></p><p>&nbsp;</p><p>Early onset diarrhoea may be accompanied by cholinergic symptoms such as rhinitis, increased salivation, flushing, diaphoresis, bradycardia, miosis and hyperperistalsis. In case of cholinergic symptoms atropine should be administered.</p><p><u>Acute infusion and related reactions</u></p><p>&nbsp;</p><p>Infusion reactions primarily consisting of rash, urticaria, periorbital oedema or pruritus were reported in patients receiving ONIVYDE pegylated liposomal treatment. New events (all grade 1 or grade 2) occurred generally early during ONIVYDE pegylated liposomal treatment, with only 2 out</p><p>of 10 patients noted with events after the fifth dose. Hypersensitivity reactions, including acute infusion reaction, anaphylactic/anaphylactoid reaction and angioedema may occur. ONIVYDE pegylated liposomal should be discontinued in case of severe hypersensitivity reactions.</p><p>&nbsp;</p><p><u>Prior Whipple procedure</u></p><p>&nbsp;</p><p>Patients with a history of a Whipple procedure have a higher risk of serious infections following ONIVYDE pegylated liposomal in combination with 5-FU and leucovorin (see section 4.8). Patients should be monitored for signs of infections.</p><p><u>Vascular disorders</u></p><p>&nbsp;</p><p>Onivyde pegylated liposomal has been associated with thromboembolic events such as pulmonary embolism, venous thrombosis and arterial thromboembolism. A thorough medical history should be obtained in order to identify patients with multiple risk factors in addition to the underlying neoplasm. Patients should be informed about the signs and symptoms of thromboembolism and advised to contact their physician or nurse immediately if any such signs or symptoms should occur.</p><p>&nbsp;</p><p><u>Pulmonary toxicity</u></p><p>&nbsp;</p><p>Interstitial Lung Disease (ILD)-like events leading to fatalities have occurred in patients receiving non-liposomal irinotecan. No cases of ILD-like events have been reported with ONIVYDE pegylated liposomal therapy in clinical studies. Risk factors include pre-existing lung disease, use of pneumotoxic medicinal products, colony stimulating factors or having previously received radiation therapy. Patients with risk factors should be closely monitored for respiratory symptoms before and during ONIVYDE pegylated liposomal therapy. A reticulo-nodular pattern on chest X-ray was observed in a small percentage of patients enrolled in a clinical study with irinotecan. New or</p><p>progressive dyspnoea, cough, and fever should prompt interruption of ONIVYDE pegylated liposomal treatment, pending diagnostic evaluation. ONIVYDE pegylated liposomal should be discontinued in patients with a confirmed diagnosis of ILD.</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>&nbsp;</p><p>Patients with hyperbilirubinaemia had higher concentrations for total SN-38 (see section 5.2) and therefore the risk of neutropenia is increased. Regular monitoring of complete blood counts should be conducted in patients with total bilirubin of 1.0-2.0 mg/dl. Caution should be exercised in patients with hepatic impairment (bilirubin &gt; 2 times upper limit of normal [ULN]; transaminases &gt; 5 times ULN). Caution is required when ONIVYDE pegylated liposomal is given in combination with other hepatotoxic medicinal products, especially in patients with pre-existing hepatic impairment.</p><p><u>Renal impairment</u></p><p>&nbsp;</p><p>The use of ONIVYDE pegylated liposomal in patients with significant renal impairment has not been established (see section 5.2).</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="Graphic_x0020_4"
 o:spid="_x0000_s1026" style='position:absolute;left:0;text-align:left;
 margin-left:70.9pt;margin-top:11.5pt;width:238.2pt;height:.5pt;z-index:15729152;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 v-text-anchor:top' coordsize="3025140,6350" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" path="m3025140,l,,,6096r3025140,l3025140,xe" fillcolor="black" stroked="f">
 <v:path arrowok="t"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="317" height="1" src="file:///C:/Users/HNHZ_SA1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" />Underweight patients (body mass index &lt; 18.5 kg/m<sup>2</sup>)</p><p>In the clinical study evaluating ONIVYDE pegylated liposomal +5-FU/LV, 5 of 8 underweight patients experienced Grade 3 or 4 adverse reactions, mostly myelosuppression, while 7 of the</p><p>8 patients required dose modification such as dose delay, dose reduction or dose discontinuation. Caution should be exercised when using ONIVYDE pegylated liposomal in patients with body mass index &lt; 18.5 kg/m<sup>2</sup>.</p><p>&nbsp;</p><p><u>Excipients</u></p><p>&nbsp;</p><p>This medicinal product contains 33,1 mg sodium per vial, equivalent to 1,65% of the WHO recommended maximum daily intake of 2g sodium for an adult.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Information about drug interactions with ONIVYDE pegylated liposomal is referenced from the published scientific literature for nonliposomal irinotecan.</p><p>&nbsp;</p><p><u>Interaction affecting the use of ONIVYDE </u>pegylated liposomal</p><p>&nbsp;</p><p><em>Strong CYP3A4 inducers</em></p><p>Patients receiving concomitant non-liposomal irinotecan and CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital or carbamazepine have substantially reduced exposure to irinotecan (AUC reduction by 12% with St John&rsquo;s wort, 57%-79% with phenytoin, phenobarbital, or carbamazepine) and SN-38 (AUC reduction by 42% with St John&rsquo;s wort, 36%-92% with phenytoin phenobarbital, or carbamazepine). Therefore, co-administration of ONIVYDE pegylated liposomal with inducers of CYP3A4 may reduce systemic exposure of ONIVYDE pegylated liposomal.</p><p><em>Strong CYP3A4 inhibitors and UGT1A1 inhibitors</em></p><p>&nbsp;</p><p>Patients receiving concomitant non-liposomal irinotecan and ketoconazole, a CYP3A4 and UGT1A1 inhibitor, have increased SN-38 exposure by 109%. Therefore, co-administration of ONIVYDE pegylated liposomal with other inhibitors of CYP3A4 (e.g. grapefruit juice, clarithromycin, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telaprevir, voriconazole) may increase systemic exposure of ONIVYDE pegylated liposomal. Based</p><p>on the drug interaction of non-liposomal irinotecan and ketoconazole, co-administration of ONIVYDE pegylated liposomal with other inhibitors of UGT1A1 (e.g. atazanavir, gemfibrozil, indinavir, regorafenib) may also increase systemic exposure of ONIVYDE pegylated liposomal.</p><p>Co-administration of ONIVYDE pegylated liposomal +5-FU/LV does not alter the pharmacokinetics of ONIVYDE pegylated liposomal based on the population pharmacokinetic analysis.</p><p><em>Antineoplastic agents </em>(including flucytosine as a prodrug for 5-fluorouracil)</p><p>Adverse effects of irinotecan, such as myelosuppression, may be exacerbated by other antineoplastic agents having a similar adverse-effect profile.</p><p>No interaction of ONIVYDE pegylated liposomal with other medicinal products is known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential / contraception in males and females</u></p><p>Women of childbearing potential should use effective contraception during ONIVYDE pegylated liposomal treatment and 7 months thereafter. Males should use condoms during ONIVYDE pegylated liposomal treatment and 4 months thereafter.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no adequate data on the use of ONIVYDE pegylated liposomal in pregnant women. ONIVYDE pegylated liposomal can cause harm to the foetus when administered to the pregnant woman, as the main ingredient irinotecan has been shown to be embryotoxic and teratogenic in animals (see section 5.3). Therefore, based on results from animal studies and the mechanism of action of irinotecan, ONIVYDE pegylated liposomal should not be used during pregnancy unless clearly necessary. If ONIVYDE pegylated liposomal is used during pregnancy or if the patient becomes pregnant while receiving therapy, the patient should be informed about the potential hazard to the foetus.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>It is unknown whether ONIVYDE pegylated liposomal or its metabolites are excreted into human milk. Because of the potential for serious adverse reactions of ONIVYDE pegylated liposomal in breast-feeding infants, ONIVYDE pegylated liposomal is contraindicated during breast-feeding (see section 4.3). Patients should not breast-feed until one month after the last dose.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>There are no data on the impact of ONIVYDE pegylated liposomal on human fertility. Non-liposomal irinotecan was shown to cause atrophy of male and female reproductive organs after multiple daily irinotecan doses in animals (see section 5.3). Prior to starting the administration of ONIVYDE pegylated liposomal consider advising patients on the preservation of gametes.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ONIVYDE pegylated liposomal has moderate influence on the ability to drive and use machines. During treatment patients should observe caution when driving or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The safety profile is based on the NAPOLI-1 clinical study. The following adverse reactions, considered to be possibly or probably related to the administration of ONIVYDE pegylated liposomal, were reported in 264 patients with metastatic adenocarcinoma of the pancreas, 147 of whom received ONIVYDE pegylated liposomal monotherapy (100 mg/m<sup>2</sup>) and 117 received ONIVYDE pegylated liposomal (70 mg/m<sup>2</sup>) in combination with 5-FU/LV.</p><p>The most common adverse reactions (incidence &ge; 20%) of ONIVYDE pegylated liposomal +5-FU/LV were: diarrhoea, nausea, vomiting, decreased appetite, neutropenia, fatigue, asthenia, anaemia, stomatitis and pyrexia. The most common serious adverse reactions (&ge; 2%) of ONIVYDE pegylated liposomal therapy were diarrhoea, vomiting, febrile neutropenia, nausea, pyrexia, sepsis, dehydration, septic shock, pneumonia, acute renal failure, and thrombocytopenia.</p><p>The rates of adverse reactions leading to permanent treatment discontinuation were 11% for the ONIVYDE pegylated liposomal +5-FU/LV arm and 12% for the monotherapy arm.</p><p>The most frequently reported adverse reactions leading to discontinuation were infection and diarrhoea for ONIVYDE pegylated liposomal +5-FU/LV arm, and vomiting and diarrhoea for the monotherapy arm.</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>The adverse reactions described in this section are derived from study data and post-marketing experience of Onivyde Pegylated Liposomal.</p><p>The adverse reactions that may occur during treatment with ONIVYDE pegylated liposomal are summarised below and are presented by system organ class and frequency category (Table 3). Within each system organ class and frequency category, adverse reactions are presented in order of decreasing seriousness. Frequencies categories used for adverse reactions are: very common (&ge; 1/10); common</p><p>(&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000) *and not known (cannot be estimated from the available data).</p><p>Table 3: Adverse reactions reported with ONIVYDE pegylated liposomal therapy</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA system organ class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction frequency*</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p><em><u>Common:</u> </em>Septic shock, Sepsis, Pneumonia, Febrile neutropenia, Gastroenteritis, Oral candidiasis</p><p><em><u>Uncommon:</u> </em>Biliary sepsis</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p><em><u>Very common:</u> </em>Neutropenia, Leukopenia, Anaemia, Thrombocytopenia</p><p><em><u>Common:</u> </em>Lymphopenia</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p><em><u>Uncommon:</u> </em>Hypersensitivity</p><p><em><u>Not known:</u> </em>Anaphylactic/Anaphylactoid reaction, Angioedema</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p><em><u>Very common:</u> </em>Hypokalaemia, Hypomagnesaemia, Dehydration, Decreased appetite</p><p><em><u>Common:</u> </em>Hypoglycaemia, Hyponatraemia, Hypophosphataemia</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p><em><u>Common:</u> </em>Insomnia</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA system organ class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction frequency*</strong></p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p><em><u>Very common:</u> </em>Dizziness</p><p><em><u>Common:</u> </em>Cholinergic syndrome, Dysgeusia</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p><em><u>Common:</u> </em>Hypotension</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p><em><u>Common</u></em><u>:</u> Pulmonary embolism, Embolism, Deep vein thrombosis</p><p><em><u>Uncommon:</u> </em>Thrombosis</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p><em><u>Common</u></em><u>: </u>Dyspnoea, Dysphonia</p><p><em><u>Uncommon:</u> </em>Hypoxia</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p><em><u>Very common:</u> </em>Diarrhoea, Vomiting, Nausea, Abdominal pain, Stomatitis</p><p><em><u>Common:</u> </em>Colitis, Haemorrhoids</p><p><em><u>Uncommon:</u> </em>Oesophagitis, Proctitis</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p><em><u>Common:</u> </em>Hypoalbuminaemia</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p><em><u>Very common:</u> </em>Alopecia</p><p><em><u>Common:</u> </em>Pruritus</p><p><em><u>Uncommon:</u> </em>Urticaria, Rash, Rash maculo-papular, Nail discolouration</p><p><em><u>Not known:</u> </em>Erythema</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p><em><u>Common:</u> </em>Acute renal failure</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p><em><u>Very common:</u> </em>Pyrexia, Peripheral oedema, Mucosal inflammation, Fatigue, Asthenia</p><p><em><u>Common:</u> </em>Infusion related reaction, Oedema</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p><em><u>Very common</u></em><u>:</u> Weight decrease</p><p><em><u>Common</u></em><u>:</u> Increased bilirubin, Increased alanine aminotransferase, Increased aspartate aminotransferase, Increased international normalised ratio</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rare occurrence cannot be estimated from the NAPOLI-1study due to the small sample size <u>Description of selected adverse reactions</u></p><p>The following adverse reactions were observed in the NAPOLI-1 clinical study:</p><p>&nbsp;</p><p><em><u>Myelosuppression</u></em></p><p>Myelosuppression (neutropenia/leukopenia, thrombocytopenia and, anaemia) was more common in the ONIVYDE pegylated liposomal +5-FU/LV arm compared to the 5-FU/LV control arm.</p><p><em>Neutropenia/leukopenia</em></p><p>Neutropenia/leukopenia was the most notable important haematological toxicity. Grade 3 or higher neutropenia occurred more frequently in patients treated with ONIVYDE pegylated liposomal</p><p>+5-FU/LV (27.4%) compared to patients treated with 5-FU/LV (1.5%). Neutropenic fever/sepsis appeared more frequently in the ONIVYDE pegylated liposomal +5-FU/LV combination arm [in 4 patients (3.4%)] compared to 5-FU/LV control arm [in 1 patient (0.7%)].</p><p>&nbsp;</p><p><em>Thrombocytopenia</em></p><p>Grade 3 or higher thrombocytopenia occurred in 2.6% of patients treated with ONIVYDE pegylated liposomal +5-FU/LV and 0% in patients treated with 5-FU/LV.</p><p><em>Anaemia</em></p><p>Grade 3 or higher anaemia occurred in 10.3% of patients treated with ONIVYDE pegylated liposomal</p><p>+5-FU/LV and in 6.7% of patients treated with 5-FU/LV.</p><p>&nbsp;</p><p><em><u>Acute renal failure</u></em></p><p>Renal impairment and acute renal failure have been identified, usually in patients who become volume depleted from nausea/vomiting and/or diarrhoea. Acute renal failure was reported in 6 of 117 patients (5.1%) in the ONIVYDE pegylated liposomal +5-FU/LV arm, 10 of 147 (6.8%) in the ONIVYDE pegylated liposomal monotherapy arm and 6 of 134 patients (4.5%) in the 5-FU/LV arm.</p><p><em><u>Diarrhoea and related adverse reactions</u></em></p><p>Diarrhoea is a very common adverse reaction leading to colitis, ileus, gastroenteritis, fatigue, dehydration, weight loss, renal toxicities, hyponatraemia, and hypokalaemia. Renal impairment and acute renal failure have been identified, usually in patients who became volume depleted from severe vomiting and/or diarrhoea. In the clinical study Grade 3 or Grade 4 diarrhoea occurred in 15 out</p><p>of 117 patients (12.8%) receiving ONIVYDE pegylated liposomal +5-FU/LV. For patients experiencing late diarrhoea, the median time to late diarrhoea onset was 8 days from the previous dose of ONIVYDE pegylated liposomal. Early onset diarrhoea, typically appearing &le; 24 hours after dose administration, can occur and is usually transient. Early onset diarrhoea may also be accompanied by cholinergic symptoms that can include rhinitis, increased salivation, flushing, diaphoresis, bradycardia, miosis and hyperperistalsis that can induce abdominal cramping. In the clinical study, early diarrhoea onset occurred in 35 patients (29.9%) and cholinergic events occurred in 4 patients (3.4%) receiving ONIVYDE pegylated liposomal +5-FU/LV.</p><p>Withhold ONIVYDE pegylated liposomal for Grade 2-4 diarrhoea and initiate treatment for diarrhoea. Following recovery to Grade 1 diarrhoea, resume ONIVYDE pegylated liposomal at a reduced dose (see section 4.2).</p><p><em><u>Infusion reaction</u></em></p><p>Acute infusion reactions were reported in 8 of 117 patients (6.8%) in the ONIVYDE pegylated liposomal +5-FU/LV arm, 3 of 147 patients (2.0%) in the ONIVYDE pegylated liposomal monotherapy arm, and 8 of 134 patients (6.0%) in the 5-FU/LV arm.</p><p><u>Other special populations</u></p><p>&nbsp;</p><p><em><u>Elderly</u></em></p><p>Overall, no major clinical differences in safety or efficacy were reported between patients &ge; 65 years and patients &lt; 65 years, although a higher frequency of discontinuation (14.8% vs 7.9%) was noted in the former group treated with ONIVYDE pegylated liposomal +5-FU/LV in the NAPOLI-1 study and in some cases the adverse reactions did not resolve. Grade 3 or higher and serious treatment emergent adverse reactions were more frequent in patients &lt; 65 years (84.1% and 50.8%) compared to</p><p>patients &ge; 65 years (68.5 % and 44.4%). Conversely, patients &gt; 75 years (n=12) experienced more frequent serious adverse reactions, dose delay, dose reduction and discontinuation compared to patients &le; 75 years (n=105) when treated with ONIVYDE pegylated liposomal +5-FU/LV in the pancreatic adenocarcinoma study.</p><p>&nbsp;</p><p><em><u>Asian population</u></em></p><p>Compared to Caucasians, Asian patients were observed with a lower incidence of diarrhoea</p><p>[14 (19.2%) out of 73 Caucasians had a &ge; Grade 3 diarrhoea, and 1 out of 33 (3.3%) Asians had a</p><p>&ge; Grade 3 diarrhoea], but a higher incidence and higher severity of neutropenia. In patients receiving ONIVYDE pegylated liposomal +5-FU/LV, the incidence of &ge; Grade 3 neutropenia was higher among Asian patients [18 of 33 (55%)] compared to Caucasian patients [13 of 73 (18%)]. Neutropenic fever/neutropenic sepsis was reported in 6% of Asian patients compared to 1% of Caucasian patients. This is consistent with the population pharmacokinetic analysis that showed a lower exposure to irinotecan and a higher exposure to its active metabolite SN-38 in Asians than in Caucasians.</p><p>&nbsp;</p><p><em><u>Patients with hepatic impairment</u></em></p><p>In clinical studies of non-liposomal irinotecan administered on a weekly dosage schedule, patients with modestly elevated baseline serum total bilirubin levels (1.0 to 2.0 mg/dl) had a significantly greater likelihood of experiencing first cycle Grade 3 or Grade 4 neutropenia than those with bilirubin levels that were less than 1.0 mg/dl.</p><p><em><u>Patients with prior Whipple procedure</u></em></p><p>In the clinical study evaluating ONIVYDE pegylated liposomal +5-FU/LV, patients with a prior Whipple procedure had a higher risk of serious infections following treatment with ONIVYDE pegylated liposomal +5-FU/LV [9 of 29 (30%)] compared to 11 of 88 (12.5%) patients with no prior Whipple procedure.</p><p><em><u>Patients with UGT1A1 allele</u></em></p><p>Individuals who are 7/7 homozygous for the UGT1A1*28 allele are at increased risk for neutropenia from non-liposomal irinotecan. In the clinical study evaluating ONIVYDE pegylated liposomal</p><p>+5-FU/LV, the frequency of &ge; Grade 3 neutropenia in these patients [2 of 7 (28.6%)] was similar to the frequency in patients not homozygous for the UGT1A1*28 allele who received a starting dose of ONIVYDE pegylated liposomal of 70 mg/m<sup>2</sup> [30 of 110 (27.3%)] (see section 5.1).</p><p><!--[if gte vml 1]><v:shape id="Graphic_x0020_5"
 o:spid="_x0000_s1026" style='position:absolute;left:0;text-align:left;
 margin-left:70.9pt;margin-top:24.05pt;width:237.6pt;height:.5pt;z-index:15729664;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 v-text-anchor:top' coordsize="3017520,6350" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" path="m3017519,l,,,6096r3017519,l3017519,xe" fillcolor="black" stroked="f">
 <v:path arrowok="t"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="317" height="1" src="file:///C:/Users/HNHZ_SA1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><em>Underweight patients (body mass index &lt; 18.5 kg/m<sup>2</sup>)</em></p><p>In the clinical study evaluating ONIVYDE pegylated liposomal +5-FU/LV, 5 of 8 underweight patients experienced a grade 3 or 4 adverse reaction, mostly myelosuppression, while 7 of</p><p>the 8 patients required dose modification such as dose delay, dose reduction or dose discontinuation (see section 4.4).</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In clinical studies, ONIVYDE pegylated liposomal was administered at doses up to 210 mg/m<sup>2</sup> to patients with various cancers. The adverse reactions in these patients were similar to those reported with the recommended dose and regimen.</p><p>&nbsp;</p><p>There have been reports of overdose with non-liposomal irinotecan at doses up to approximately twice the recommended therapeutic dose of irinotecan, which may be fatal. The most significant adverse reactions reported were severe neutropenia and severe diarrrhoea.</p><p>&nbsp;</p><p>There is no known antidote for overdose of ONIVYDE pegylated liposomal. Maximum supportive care should be instituted to prevent dehydration due to diarrhoea and to treat any infectious complications.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Topoisomerase 1 (TOP1) inhibitors. ATC Code: L01CE02. <u>Mechanism of action</u></p><p>The active substance in ONIVYDE pegylated liposomal is irinotecan (topoisomerase I inhibitor) encapsulated in a lipid bilayer vesicle or liposome.</p><p>Irinotecan is a derivative of camptothecin. Camptothecins act as specific inhibitors of the enzyme DNA topoisomerase I. Irinotecan and its active metabolite SN-38 bind reversibly to the topoisomerase I-DNA complex and induce single-strand DNA lesions which block the DNA replication fork and are responsible for the cytotoxicity. Irinotecan is metabolised by carboxylesterase to SN-38. SN-38 is approximately 1,000 times as potent as irinotecan as an inhibitor of topoisomerase I purified from human and rodent tumour cell lines.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p>In animal models, ONIVYDE pegylated liposomal has been shown to extend plasma levels of irinotecan and prolong the exposure to the active metabolite SN-38 at the site of the tumour.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p>The safety and efficacy of ONIVYDE pegylated liposomal were investigated in a multinational, randomised, open label, controlled clinical study (NAPOLI&ndash;1) that tested two treatment regimens for patients with metastatic pancreatic adenocarcinoma who had documented disease progression after gemcitabine or gemcitabine-containing therapy. The study was designed to assess the clinical efficacy and safety of ONIVYDE pegylated liposomal monotherapy or ONIVYDE pegylated liposomal</p><p>+5-FU/LV compared to an active control arm of 5-FU/LV.</p><p>&nbsp;</p><p>Patients randomised to ONIVYDE pegylated liposomal +5-FU/LV received ONIVYDE pegylated liposomal at 70 mg/m<sup>2</sup> as an intravenous infusion over 90 minutes, followed by</p><p>LV 400 mg/m<sup>2</sup> intravenously over 30 minutes, followed by 5-FU 2,400 mg/m<sup>2</sup> intravenously</p><p>over 46 hours, administered every 2 weeks. Patients homozygous for the UGT1A1*28 allele were given a lower initial dose of ONIVYDE pegylated liposomal (see section 4.2). Patients randomised to 5-FU/LV received leucovorin 200 mg/m<sup>2</sup> intravenously over 30 minutes, followed</p><p>by 5-FU 2,000 mg/m<sup>2</sup> intravenously over 24 hours, administered on Days 1, 8, 15 and 22 of a 6-week cycle. Patients randomised to ONIVYDE pegylated liposomal monotherapy received 100 mg/m<sup>2</sup> as an intravenous infusion over 90 minutes every 3 weeks.</p><p>&nbsp;</p><p>Key eligibility criteria for patients with metastatic adenocarcinoma of the pancreas in the NAPOLI-1 clinical study were Karnofsky Performance Status (KPS) &ge; 70, normal bilirubin level,</p><p>transaminase levels &le; 2.5 times the ULN or &le; 5 times the ULN for patients with liver metastases and albumin &ge; 3.0 g/dl.</p><p>A total of 417 patients were randomised to the ONIVYDE pegylated liposomal +5-FU/LV</p><p>arm (N=117), ONIVYDE pegylated liposomal monotherapy arm (N=151) and 5-FU/LV arm (N=149). Patient demographic and entry disease characteristics were well balanced between study arms.</p><p>In the intent to treat (all randomised) population, the median age was 63 years</p><p>(range 31-87 years), 57 % were males, and 61% were Caucasian and 33% were Asian. Mean baseline albumin level was 3.6 g/dl, and baseline KPS was 90-100 in 55% of patients. Disease characteristics included 68% of patients with liver metastases and 31% with lung metastases; 12% of patients had no prior lines of metastatic therapy, 56 % of patients had 1 prior line of metastatic therapy, 32% of patients had 2 or more prior lines of metastatic therapy.</p><p>&nbsp;</p><p>Patients received treatment until disease progression or unacceptable toxicity. The primary outcome measure was Overall survival (OS). Additional outcome measures included Progression free survival (PFS) and Objective response rate (ORR). Results are shown in Table 4. Overall survival is illustrated in Figure 1.</p><p>Table 4: Efficacy results from NAPOLI-1 clinical study</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>ONIVYDE pegylated liposomal +5-FU/LV (N= 117)</strong></p></td><td style="vertical-align:top"><p><strong>5-FU/LV (N= 119)</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Overall survival<sup>11</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Number of deaths, n (%)</strong></p></td><td style="vertical-align:top"><p><strong>75 (64)</strong></p></td><td style="vertical-align:top"><p><strong>80 (67)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median OS (months)</p></td><td style="vertical-align:top"><p>6.1</p></td><td style="vertical-align:top"><p>4.2</p></td></tr><tr><td style="vertical-align:top"><p>(95% Confidence Interval (CI))</p></td><td style="vertical-align:top"><p>(4.8, 8.9)</p></td><td style="vertical-align:top"><p>(3.3, 5.3)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard Ratio (95% CI)<sup>3</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.67 (0.49-0.92)</p></td></tr><tr><td style="vertical-align:top"><p>p-value<sup>4</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.0122</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Progression</strong>-<strong>free survival<sup>1,2</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Death or progression, n (%)</p></td><td style="vertical-align:top"><p>83 (71)</p></td><td style="vertical-align:top"><p>92 (77)</p></td></tr><tr><td style="vertical-align:top"><p>Median PFS (months)</p></td><td style="vertical-align:top"><p>3.1</p></td><td style="vertical-align:top"><p>1.5</p></td></tr><tr><td style="vertical-align:top"><p>(95% CI)</p></td><td style="vertical-align:top"><p>(2.7, 4.2)</p></td><td style="vertical-align:top"><p>(1.4, 1.8)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard Ratio (95% CI)<sup>3</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.56 (0.41-0.75)</p></td></tr><tr><td style="vertical-align:top"><p>p-value<sup>4</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.0001</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Objective response rate<sup>2</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>ORR (%)</p></td><td style="vertical-align:top"><p>16.2</p></td><td style="vertical-align:top"><p>0.8</p></td></tr><tr><td style="vertical-align:top"><p>95% CI of Rate<sup>5</sup></p></td><td style="vertical-align:top"><p>9.6, 22.9</p></td><td style="vertical-align:top"><p>0.0, 2.5</p></td></tr><tr><td style="vertical-align:top"><p>Rate Difference (95% CI)<sup>5</sup></p></td><td colspan="2" style="vertical-align:top"><p>15.4 (8.5, 22.3)</p></td></tr><tr><td style="vertical-align:top"><p>p-value<sup>6</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt; 0.0001</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><sup>1</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Median is the Kaplan-Meier estimate of the median survival time</p><p><sup>2</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Per RECIST guidelines, v 1.1.</p><p><sup>3</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cox model analysis</p><p><sup>4</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unstratified log-rank test</p><p><sup>5</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on Normal approximation</p><p><sup>6</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fisher&rsquo;s exact test</p><p>Abbreviations: 5-FU/LV=5-fluorouracil/leucovorin; CI=confidence interval</p><p>&nbsp;</p><p>Figure 1: Overall survival</p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
  path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="if lineDrawn pixelLineWidth 0"/>
   <v:f eqn="sum @0 1 0"/>
   <v:f eqn="sum 0 0 @1"/>
   <v:f eqn="prod @2 1 2"/>
   <v:f eqn="prod @3 21600 pixelWidth"/>
   <v:f eqn="prod @3 21600 pixelHeight"/>
   <v:f eqn="sum @0 0 1"/>
   <v:f eqn="prod @6 1 2"/>
   <v:f eqn="prod @7 21600 pixelWidth"/>
   <v:f eqn="sum @8 21600 0"/>
   <v:f eqn="prod @7 21600 pixelHeight"/>
   <v:f eqn="sum @10 21600 0"/>
  </v:formulas>
  <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
  <o:lock v:ext="edit" aspectratio="t"/>
 </v:shapetype><v:shape id="Image_x0020_6" o:spid="_x0000_s1026" type="#_x0000_t75"
  alt="þÿ" style='position:absolute;margin-left:70.9pt;margin-top:15.5pt;
  width:238.15pt;height:176.65pt;z-index:-15727104;visibility:visible;
  mso-wrap-style:square;mso-wrap-distance-left:0;mso-wrap-distance-top:0;
  mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
  mso-position-vertical:absolute;mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/HNHZ_SA1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
   o:title="þÿ"/>
  <o:lock v:ext="edit" aspectratio="f"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><strong>&nbsp;<img src="data:image/png;base64,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" alt="" width="463" height="350" vspace="0" hspace="0" border="0" style="width:463px;height:350px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></strong></p><p>In the limited number of patients with prior exposure to non-liposomal irinotecan, no benefit of ONIVYDE pegylated liposomal has been demonstrated.</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with ONIVYDE pegylated liposomal in all subsets of the paediatric population in treatment of adenocarcinoma of the pancreas (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>&nbsp;</p><p>Liposome encapsulation of irinotecan extends circulation and limits distribution relative to those of the non-liposomal irinotecan.</p><p>The plasma pharmacokinetics of total irinotecan and total SN-38 were evaluated in patients with cancer who received ONIVYDE pegylated liposomal, as a single agent or as part of combination chemotherapy, at doses between 50 and 155 mg/m<sup>2</sup>. The pharmacokinetic parameters of total irinotecan and SN-38 analytes, following the administration of ONIVYDE pegylated liposomal 70 mg/m<sup>2</sup> are presented in Table 5.</p><p>Table 5: Summary of mean (&plusmn;standard deviation) total irinotecan and total SN-38</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Analyte</strong></p></td><td style="vertical-align:top"><p><strong>PK parameters</strong></p></td><td style="vertical-align:top"><p><strong>Unit</strong></p></td><td style="vertical-align:top"><p><strong>ONIVYDE pegylated liposomal</strong></p><p><strong>geomean (95% CI)<sup>a</sup></strong></p><p><strong>70 mg/m<sup>2</sup> (n=353)<sup>b</sup></strong></p></td><td style="vertical-align:top"><p><strong>Non</strong>-<strong>liposomal irinotecan </strong><strong>mean (SD)</strong></p><p><strong>125 mg/m<sup>2</sup> (n=99)<sup>c</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Total</p></td><td style="vertical-align:top"><p>AUC</p></td><td style="vertical-align:top"><p>h&times;ng/ml</p></td><td style="vertical-align:top"><p>919,228</p></td><td style="vertical-align:top"><p>10,529</p></td></tr><tr><td style="vertical-align:top"><p>irinotecan</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(845,653-999,204)</p></td><td style="vertical-align:top"><p>(3,786)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cmax</p></td><td style="vertical-align:top"><p>ng/ml</p></td><td style="vertical-align:top"><p>28,353</p></td><td style="vertical-align:top"><p>1,492</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(27,761-28,958)</p></td><td style="vertical-align:top"><p>(452)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Clearance (CL)</p></td><td style="vertical-align:top"><p>l/h/m<sup>2</sup></p></td><td style="vertical-align:top"><p>0.087</p></td><td style="vertical-align:top"><p>13.0</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(0.080-0.094)</p></td><td style="vertical-align:top"><p>(5.6)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Volume (V)</p></td><td style="vertical-align:top"><p>l/m<sup>2</sup></p></td><td style="vertical-align:top"><p>2.6</p></td><td style="vertical-align:top"><p>138</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(2.6-2.7)</p></td><td style="vertical-align:top"><p>(60.9)</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Analyte</strong></p></td><td style="vertical-align:top"><p><strong>PK parameters</strong></p></td><td style="vertical-align:top"><p><strong>Unit</strong></p></td><td style="vertical-align:top"><p><strong>ONIVYDE pegylated liposomal</strong></p><p><strong>geomean (95% CI)<sup>a</sup></strong></p><p><strong>70 mg/m<sup>2</sup> (n=353)<sup>b</sup></strong></p></td><td style="vertical-align:top"><p><strong>Non</strong>-<strong>liposomal irinotecan </strong><strong>mean (SD)</strong></p><p><strong>125 mg/m<sup>2</sup> (n=99)<sup>c</sup></strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>t1/2 effective</p></td><td style="vertical-align:top"><p>h</p></td><td style="vertical-align:top"><p>20.8</p></td><td style="vertical-align:top"><p>6.07</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(19.4-22.3)</p></td><td style="vertical-align:top"><p>(1.19)</p></td></tr><tr><td style="vertical-align:top"><p>Total</p></td><td style="vertical-align:top"><p>AUC</p></td><td style="vertical-align:top"><p>h&times;ng/ml</p></td><td style="vertical-align:top"><p>341</p></td><td style="vertical-align:top"><p>267</p></td></tr><tr><td style="vertical-align:top"><p>SN-38</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(326-358)</p></td><td style="vertical-align:top"><p>(115)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cmax</p></td><td style="vertical-align:top"><p>ng/ml</p></td><td style="vertical-align:top"><p>3.0</p></td><td style="vertical-align:top"><p>27.8</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(2.9-3.1)</p></td><td style="vertical-align:top"><p>(11.6)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>t1/2 effective</p></td><td style="vertical-align:top"><p>h</p></td><td style="vertical-align:top"><p>40.9</p></td><td style="vertical-align:top"><p>11.7</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(39.8-42.0)</p></td><td style="vertical-align:top"><p>(4.29)</p></td></tr></tbody></table><p>SD= standard deviation</p><p>AUC= area under the plasma concentration curve (extrapolated to infinity for ONIVYDE pegylated liposomal and AUC24h for non-liposomal irinotecan)</p><p>Cmax= maximum plasma concentration t1/2 effective= effective half-lives</p><p><sup>a</sup>Values are estimated from population PK analysis</p><p><sup>b</sup>N=353 refers to all the subjects included in the population PK analysis</p><p><sup>c</sup>Values are obtained from published data [Schaaf LJ et al. <em>Clin Cancer Res</em>. 2006 Jun 15;12:3782-91] <u>Distribution</u></p><p>Direct measurement of liposomal irinotecan shows that 95% of irinotecan remains</p><p>liposome-encapsulated during circulation. Non-liposomal irinotecan displays a large volume of distribution (138 l/m<sup>2</sup>). The volume of distribution of ONIVYDE pegylated</p><p>liposomal 70 mg/m<sup>2</sup> was 2.6 l/m<sup>2</sup>, which suggests that ONIVYDE pegylated liposomal is largely confined to vascular fluid.</p><p>The plasma protein binding of ONIVYDE pegylated liposomal is negligible (&lt; 0.44% of total irinotecan in ONIVYDE pegylated liposomal). The plasma protein binding of non-liposomal irinotecan is moderate (30% to 68%), and SN-38 is highly bound to human plasma proteins (approximately 95%).</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>Irinotecan released from liposome encapsulation follows a similar metabolic pathway reported with non-liposomal irinotecan.</p><p>The metabolic conversion of irinotecan to the active metabolite SN-38 is mediated by carboxylesterase enzymes<em>. In vitro </em>studies indicate that irinotecan, SN-38 and another metabolite aminopentane carboxylic acid (APC) do not inhibit cytochrome P-450 isozymes. SN-38 is subsequently conjugated predominantly by the enzyme UDP-glucuronosyl transferase 1A1 (UGT1A1) to form a glucuronide metabolite. UGT1A1 activity is reduced in individuals with genetic polymorphisms that lead to reduced enzyme activity such as the UGT1A1*28 polymorphism. In the population pharmacokinetic analysis in patients with ONIVYDE pegylated liposomal using the results of a subset with UGT1A1*28 genotypic testing, in which the analysis adjusted for the lower dose administered to patients homozygous for the UGT1A1*28 allele, patients homozygous (N=14) and non-homozygous (N=244) for this allele had total SN-38 average steady-state concentrations of 1.06 and 0.95 ng/ml, respectively.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>The disposition of ONIVYDE pegylated liposomal and non-liposomal irinotecan has not been fully elucidated in humans.</p><p>The urinary excretion of non-liposomal irinotecan is 11% to 20%; SN-38 &lt; 1%; and</p><p>SN-38 glucuronide is 3%. The cumulative biliary and urinary excretion of irinotecan and its metabolites (SN-38 and SN-38 glucuronide) over a period of 48 hours following administration of</p><p>&nbsp;</p><p>non-liposomal irinotecan in two patients ranged from approximately 25% (100 mg/m<sup>2</sup>) to 50% (300 mg/m<sup>2</sup>).</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>&nbsp;</p><p>No dedicated pharmacokinetic study has been conducted in patients with renal impairment. In a population pharmacokinetic analysis, mild-to-moderate renal impairment had no effect on the exposure of total SN-38 after adjusting for body surface area (BSA). The analysis included 68 patients with moderate (CLcr 30-59 ml/min), 147 patients with mild (CLcr 60-89 ml/min) renal impairment, and 135 patients with normal renal function (CLcr &gt; 90 ml/min). There was insufficient data in patients with severe renal impairment (CLcr &lt; 30 ml/min) to assess its effect on pharmacokinetics (see sections 4.2 and 4.4).</p><p><u>Hepatic impairment</u></p><p>&nbsp;</p><p>No dedicated pharmacokinetic study has been conducted in patients with hepatic impairment. In a population pharmacokinetic analysis, patients with baseline total bilirubin concentrations of 1-2 mg/dl (n=19) had average steady state concentrations for total SN-38 that were increased</p><p>by 37% (0.98 [95%CI: 0.94-1.02] and 1.29 [95%CI: 1.11-1.5] ng/ml, respectively) compared to patients with baseline bilirubin concentrations of &lt; 1 mg/dl (n=329); however, there was no effect of elevated ALT/AST concentrations on total SN-38 concentrations. No data are available in patients with total bilirubin more than 2 times the ULN.</p><p>&nbsp;</p><p><u>Other special populations</u></p><p>&nbsp;</p><p><em>Age and gender</em></p><p>The population pharmacokinetic analysis in patients aged 28 to 87 years, of whom 11% were</p><p>&ge;75 years suggests that age had no clinically meaningful effect on the exposure to irinotecan and SN-38.</p><p>The population pharmacokinetic analysis in 196 male and 157 female patients suggests that gender had no clinically meaningful effect on the exposure to irinotecan and SN-38 after adjusting for BSA.</p><p><em>Ethnicity</em></p><p>The population pharmacokinetic analysis suggest that Asians have 56% lower total irinotecan average steady state concentration (3.93 [95%CI: 3.68-4.2] and 1.74 [95%CI: 1.58-1.93] mg/l, respectively) and 8% higher total SN-38 average steady state concentration (0.97 [95%CI: 0.92-1.03]</p><p>and 1.05 [95%CI: 0.98-1.11] ng/ml, respectively) than Caucasians. <u>Pharmacokinetic/pharmacodynamic relationship</u></p><p>In a pooled analysis from 353 patients, higher plasma SN-38 Cmax was associated with increased likelihood of experiencing neutropenia, and higher plasma total irinotecan Cmax was associated with increased likelihood of experiencing diarrhoea.</p><p>In the clinical study demonstrating effectiveness of ONIVYDE pegylated liposomal, higher plasma exposures of total irinotecan and SN-38 for patients in the ONIVYDE pegylated liposomal +5-FU/LV treatment arm were associated with longer OS and PFS as well as with higher ORR (objective response rate).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In single and repeated dose toxicity studies in mice, rats and dogs, the target organs of toxicity were the gastrointestinal tract and the hematologic system. The severity of effects was dose-related and reversible. The no-observed-adverse-effect level (NOAEL) in rats and dogs following 90 min intravenous infusion of ONIVYDE pegylated liposomal once every 3 weeks for 18 weeks was</p><p>155 mg/m<sup>2</sup>.</p><p>&nbsp;</p><p>In safety pharmacology studies in dogs, ONIVYDE pegylated liposomal had no effect on cardiovascular, hemodynamic, electrocardiographic, or respiratory parameters at doses up to 18 mg/kg or 360 mg/m<sup>2</sup> . No findings indicative of CNS related toxicity were observed in the repeated dose toxicity studies in rats.</p><p>&nbsp;</p><p><u>Genotoxic and carcinogenic potential</u></p><p>No genotoxicity studies have been performed with ONIVYDE pegylated liposomal. Non-liposomal irinotecan and SN-38 were genotoxic <em>in vitro </em>in the chromosomal aberration test on CHO-cells as well as in the <em>in vivo </em>micronucleus test in mice. However, in other studies with irinotecan they have been shown to be devoid of any mutagenic potential in the Ames test.</p><p>No carcinogenicity studies have been performed with ONIVYDE pegylated liposomal. For non-liposomal irinotecan, in rats treated once a week during 13 weeks at the maximum dose</p><p>of 150 mg/m&sup2;, no treatment related tumours were reported 91 weeks after the end of treatment. Under these conditions, there was a significant linear trend with dose for the incidence of combined uterine horn endometrial stromal polyps and endometrial stromal sarcomas. Due to its mechanism of action, irinotecan is considered a potential carcinogen.</p><p>&nbsp;</p><p><u>Reproduction toxicity</u></p><p>&nbsp;</p><p>No reproductive and developmental toxicity studies have been performed with ONIVYDE pegylated liposomal.</p><p>Non-liposomal irinotecan was teratogenic in rats and rabbits at doses below the human therapeutic dose. In rats, pups born from treated animals and having external abnormalities showed a decrease in fertility. This was not seen in morphologically normal pups. In pregnant rats there was a decrease in placental weight and in the offspring a decrease in foetal viability and increase in behavioural abnormalities.</p><p>Non-liposomal irinotecan caused atrophy of male reproductive organs both in rats and dogs after multiple daily doses of 20 mg/kg and 0.4 mg/kg, respectively.These effects were reversible upon cessation of treatment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Liposome forming lipids</u></p><p>1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) Cholesterol</p><p>N-(carbonyl-methoxypolyethylene glycol-2000)-1, 2-distearoly-sn-glycero-3-phosphoethanolamine (MPEG-2000-DSPE)</p><p>&nbsp;</p><p><u>Other excipients</u> Sucrose octasulphate</p><p>2- [ 4- (2-Hydroxyethyl)piperazin-1-yl] ethanesulfonic acid (HEPES buffer) Sodium chloride</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ONIVYDE pegylated liposomal must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vial
 
3 years.

After dilution
Chemical and physical stability for the diluted dispersion for infusion has been demonstrated at 15-25°C for up to 6 hours or in the refrigerator (2ºC-8ºC) for no more than 24 hours.
From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C-8&deg;C). Do not freeze.</p><p>Keep the vial in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>For storage conditions after dilution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Type I glass vial with a grey chlorobutyl stopper and an aluminium seal with a flip-off cap, containing 10 ml of concentrate.</p><p>Each pack contains one vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>ONIVYDE pegylated liposomal is a cytotoxic medicinal product, and caution should be exercised in handling it. The use of gloves, goggles and protective clothing when handling or administering ONIVYDE pegylated liposomal is recommended. If the dispersion contacts the skin, the skin should be washed immediately and thoroughly with soap and water. If the dispersion contacts mucous membranes, they should be flushed thoroughly with water. Pregnant staff should not handle ONIVYDE pegylated liposomal considering the cytotoxic nature of the medicinal product.</p><p>&nbsp;</p><p><u>Preparation of the dispersion and administration</u></p><p>&nbsp;</p><p>ONIVYDE pegylated liposomal is supplied as a sterile liposomal dispersion at a concentration of 4.3 mg/ml and must be diluted prior to administration using a needle not larger than 21 gauge.</p><p>Dilute with 5% glucose solution for injection or sodium chloride 9 mg/ml (0.9%) solution for injection to prepare a dispersion of the appropriate dose of ONIVYDE pegylated liposomal diluted to a final volume of 500 ml. Mix the diluted dispersion by gentle inversion. The diluted dispersion is clear to slightly white to slightly opalescent and free from visible particles.</p><p>ONIVYDE pegylated liposomal should be administered before LV followed by 5-FU. ONIVYDE pegylated liposomal must not be administered as a bolus injection or an undiluted dispersion.</p><p>Aseptic techniques must be followed during the preparation of the infusion. ONIVYDE pegylated liposomal is for single use only.</p><p>Care should be taken to avoid extravasation, and the infusion site should be monitored for signs of inflammation. Should extravasation occur, flushing the site with sodium chloride 9 mg/ml (0.9%) solution for injection and/or sterile water and applications of ice are recommended.</p><p>&nbsp;</p><p>For storage conditions after dilution of the medicinal product, see section 6.3.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Les Laboratoires Servier 50, rue Carnot
92284 Suresnes cedex France

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 22 August 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>